Medicare’s June 25, 2026 Update for Implantable CGM Coverage

ByBrian “Weence” Bateman

CMS updated its local Medicare coverage policy for implantable CGMs on June 25, 2026. Here’s what eligibility typically depends on, what to document for your visit, and key safety/practical limits.

If you’re on Medicare and considering an implantable continuous glucose monitor (I-CGM), the most practical takeaway is this: coverage depends on meeting specific medical-necessity and documentation requirements in CMS’s Local Coverage Determination (LCD).

CMS posted a June 25, 2026 revision to its LCD for I-CGMs. CMS describes that revision as formatting/grammar updates with no coverage-criteria change. The steps below translate the LCD’s “who qualifies” language into plain language and share practical questions to take to your clinician.

What an implantable CGM (I-CGM) is

An I-CGM is a diabetes technology that continuously estimates glucose levels and sends data to a mobile app.

  • Implanted sensor + app display: With the FDA-approved Eversense E3 system, a small sensor is implanted under the skin by a clinician. Data are transmitted wirelessly to a compatible smart device.
  • Alerts: The app can alert you when glucose values approach user-configured high or low thresholds.
  • Calibration still matters: The Eversense E3 system uses a calibration schedule that requires fingerstick-based calibration (more frequent early after implantation, then less frequent afterward).
  • App/phone dependency: Correct functioning depends on the mobile device supporting the system’s connectivity and app settings.

Important expectation setting: CGMs measure glucose in the fluid between cells (interstitial glucose), and readings may differ from blood glucose at certain times. If CGM results don’t match how you feel, clinicians often recommend using a confirmatory blood glucose check.

The CMS update on June 25, 2026—what changed (and what didn’t)

In CMS’s LCD L38686, the revision posted June 25, 2026 applies to Medicare dates of service on or after that date. CMS notes the update was a biennial review and describes it as formatting and grammatical changes only, with no coverage-criteria changes.

CMS also reiterates a key limitation: I-CGMs are not intended for short-term diagnostic use (CMS defines short-term diagnostic use as 72 hours to 1 week).

Who may qualify under the current LCD

Under CMS’s “reasonable and necessary” framework, you generally need the right diagnosis context, a prescription aligned with FDA indications, and documentation showing you meet at least one clinical criterion—most commonly:

  • Insulin-treated (eligible if the beneficiary is insulin-treated), or
  • Documented problematic hypoglycemia (with documentation that matches the LCD’s event definitions).

Problematic hypoglycemia—typical LCD thresholds and definitions

  • Recurrent “level 2” hypoglycemia: more than one event with glucose <54 mg/dL that persists despite multiple (more than one) attempts to adjust medications and/or modify the treatment plan.
  • One “level 3” hypoglycemic event: glucose <54 mg/dL plus altered mental and/or physical state requiring third-party assistance to treat hypoglycemia.

Switching between CGM types: CMS may address situations where a beneficiary switches to an implantable CGM after previously meeting coverage criteria for another CGM category. Even when switching is discussed, the LCD’s underlying clinical documentation expectations still apply.

Documentation checklist to bring to your clinician visit

To help your clinician document medical necessity under the LCD, gather information that supports either insulin treatment or problematic hypoglycemia history. This is not personal medical advice—just a practical way to make the coverage discussion smoother.

  • Diabetes diagnosis details: Ask your clinician what diagnosis information they need reflected in the prescription paperwork.
  • If insulin-treated: Bring a brief summary of your insulin regimen (what you take and how/when).
  • If qualifying via hypoglycemia: For each qualifying event, be ready to provide details such as:
    • Date/time of the episode
    • Measured glucose value meeting the LCD threshold (<54 mg/dL)
    • For recurrent level 2: evidence that more than one attempt was made to adjust medications and/or the treatment plan—and hypoglycemia persisted
    • For level 3: what changed in mental/physical status and whether third-party help was required
  • Training plan: CMS expects the treating practitioner to conclude that you (or a caregiver) has sufficient training to use the I-CGM; ask how that will be documented.
  • Prescription matches FDA-labeled use: Ask your clinician to confirm the prescription is aligned with the device’s indicated use.

What ongoing coverage typically requires

CMS’s LCD describes ongoing coverage support that generally includes follow-up visits every 6 months after the initial I-CGM prescription. The treating practitioner documents things like adherence to the regimen and how the device fits into the diabetes treatment plan. (CMS allows in-person or Medicare-approved telehealth for the required follow-ups.)

Implantable CGM safety and practical limits to understand

Implantable CGMs aren’t “set it and forget it.” Practical use involves device care, calibration/verification, and planning for certain medical procedures.

  • Implant procedure is required: For Eversense E3, the sensor is implanted under the skin by a clinician.
  • MRI planning: The Eversense E3 smart transmitter is not MRI compatible, and it must be removed before MRI.
  • Calibration schedule: The system requires fingerstick-based calibration more frequently early after implantation, then less frequently afterward (per the FDA instructions).
  • Reading interpretation limits: CGM readings are estimates based on interstitial glucose. If symptoms don’t match the monitor, confirm with a fingerstick blood glucose check per clinician guidance.
  • Potential interferences in healthcare settings: FDA notes that certain sugar alcohol exposures (such as mannitol or sorbitol) in healthcare contexts may affect sensor readings (for example, causing false high results).

When to seek urgent help: If you experience severe hypoglycemia symptoms—such as confusion, inability to eat or drink safely, seizure, or loss of consciousness—seek emergency care immediately (call 911 or local emergency services). Don’t wait to see if an alert resolves.

What to ask your clinician/Medicare next (step-by-step)

  1. Which LCD criterion do I meet? Confirm whether your documentation supports insulin-treated status or the problematic hypoglycemia definition (including thresholds and event details).
  2. How will my training be documented? Ask what evidence the prescription or clinical note should include to satisfy the LCD training expectation.
  3. Is this prescription aligned with FDA indications? Confirm the intended use matches the device’s labeling.
  4. If it’s hypoglycemia-related, what exact details are needed? Review whether your notes include date/time, glucose values, and (for level 2) evidence of multiple treatment-plan adjustment attempts—or (for level 3) the need for third-party assistance.
  5. What happens at 6 months? Ask what the 6-month follow-up documentation should cover and whether your provider will use in-person or Medicare-approved telehealth.
  6. How should I handle calibration and “mismatch” situations? Ask for a clear plan for calibration follow-through and when to confirm CGM readings with fingersticks.
  7. Do I need an MRI plan? If MRI might be part of your care, ask how and when the transmitter should be handled.

Bottom line: CMS says the June 25, 2026 LCD revision didn’t change coverage criteria, but eligibility still hinges on the right prescription context and detailed documentation—especially around insulin treatment and/or problematic hypoglycemia events.

Evidence note: A randomized cross-over study comparing implantable and transcutaneous CGM experiences found differences in accuracy and patient-reported acceptance; as with many device studies, results can vary by setting and the study’s specific design and sample size.

Key sources

Editorial note: Weence articles are researched from cited public-health, medical, regulatory, journal, and reputable news sources and may be drafted with AI assistance. They are checked for source support, clarity, and safety guardrails before publication.

This article is for general informational purposes only and is not medical advice. Research findings can be early or incomplete, and health guidance can change. Always talk with a qualified healthcare professional about personal symptoms, diagnosis, medications, vaccines, screenings, or treatment decisions. If you think you may have a medical emergency, call emergency services right away.

Related

Brian “Weence” Bateman is a health and medical writer who covers public health updates, healthcare policy, and medical developments affecting communities across the United States. He works closely with dentists and healthcare providers and focuses on making complex medical information clear, accurate, and useful for everyday readers.